Does Mounjaro Cause Gallstones?
Mounjaro (tirzepatide), a GLP-1/GIP receptor agonist for type 2 diabetes and weight loss, carries a risk of gallbladder-related issues, including gallstones (cholelithiasis). Clinical trials showed 1.9% of Mounjaro users developed gallstones or biliary sludge, compared to 0.4% on placebo.[1][2] This risk rises with rapid weight loss, a known trigger for gallstones, as Mounjaro promotes substantial weight reduction (up to 20% body weight in studies).[3]
Post-marketing reports and FDA labeling confirm cholelithiasis as an adverse reaction, with some cases requiring cholecystectomy (gallbladder removal).[1][4]
How Common Is This Side Effect?
In the SURPASS trials (phases 2-3), gallbladder disorders occurred in:
- 0.6% on 5 mg dose
- 1.9% overall across higher doses
- Higher with longer use or greater weight loss[2][5]
Real-world data from VA studies on similar GLP-1 drugs (e.g., semaglutide) show 1.5-2.5 times higher gallstone risk versus non-users.[6] Mounjaro's dual mechanism may amplify this slightly over single GLP-1s.[3]
Why Does It Happen?
GLP-1 agonists like Mounjaro slow gallbladder emptying (cholecystokinin effect), leading to bile stasis and stone formation.[7] Rapid fat loss mobilizes cholesterol into bile, oversaturating it.[8] Risk factors include female sex, obesity history, age over 40, and doses above 10 mg weekly.[1][2]
What Are Symptoms and When Do They Appear?
Symptoms mimic typical gallstones: upper abdominal pain (often post-meal), nausea, vomiting, or jaundice. Onset averages 3-12 months into treatment, tied to peak weight loss.[2][4] Acute cholecystitis (inflamed gallbladder) affects ~0.2-0.5% of users.[5]
Can You Prevent Gallstones on Mounjaro?
No proven prevention, but:
- Start low (2.5 mg) and titrate slowly to minimize rapid weight loss.
- Maintain hydration and balanced diet; some doctors suggest ursodiol for high-risk patients.
- Monitor with ultrasound if symptoms arise—baseline scans aren't routine.[1][9]
Discontinue if severe symptoms occur; most resolve without stopping the drug.[4]
How Does Mounjaro Compare to Ozempic or Wegovy?
All GLP-1s carry similar warnings, but trial data shows:
| Drug | Gallbladder Events (%) | Relative Risk vs Placebo |
|------|-------------------------|--------------------------|
| Mounjaro (15 mg) | 2.1 [2] | 4.5x |
| Ozempic (1 mg) | 1.5 [10] | 3.1x |
| Wegovy (2.4 mg) | 2.6 [11] | 5.7x |
Mounjaro's risk aligns closely, potentially higher due to greater weight loss efficacy.[3][12]
What Do Patients Report and Next Steps?
User forums (e.g., Reddit, Drugs.com) frequently mention gallstone surgeries after 6+ months on Mounjaro, often with 15-30 lb monthly loss.[13] Consult a doctor for abdominal pain; imaging confirms stones. Eli Lilly notes no causal proof beyond association.[1]
[1]: Mounjaro Prescribing Information (FDA)
[2]: SURPASS-1 to -5 trials (NEJM, Lancet 2021-2022)
[3]: Tirzepatide overview (JAMA 2022)
[4]: FDA Adverse Event Reporting System (FAERS) summaries
[5]: Eli Lilly safety data (ClinicalTrials.gov)
[6]: VA study on GLP-1s (Gastroenterology 2023)
[7]: GLP-1 gallbladder mechanism (Diabetes Care 2021)
[8]: Weight loss and cholelithiasis review (Obesity Reviews 2019)
[9]: AGA guidelines on GLP-1 gallstone risk
[10]: SUSTAIN trials (Ozempic)
[11]: STEP trials (Wegovy, NEJM 2021)
[12]: Head-to-head GLP-1 comparisons (Endocrinology 2024)
[13]: Patient reviews (Drugs.com, aggregated 2023-2024)